Skip to main content
Guizhou Bailing Group Pharmaceutical Co., Ltd. logo

Guizhou Bailing Group Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002424 ISIN · CNE100000PY3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,405 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002424

About Guizhou Bailing Group Pharmaceutical Co., Ltd.

https://www.gzbl.com

Guizhou Bailing Group Pharmaceutical Co., Ltd. focuses on the research, development, production, and distribution of pharmaceutical products, with a specialized emphasis on Traditional Chinese Medicine (TCM) and ethnic Miao medicines. The company’s product portfolio covers a wide range of therapeutic areas, including respiratory health, cardiovascular diseases, and diabetes management. Notable products include cough syrups, capsules for cardiovascular health, and treatments derived from indigenous botanical sources. Guizhou Bailing integrates modern pharmaceutical technology with traditional herbal knowledge to develop standardized treatments. The company operates large-scale manufacturing bases and maintains a robust research and development infrastructure dedicated to clinical trials and the modernization of ethnic medicine. Its strategic focus involves the industrialization of traditional formulas to address chronic health conditions through evidence-based herbal pharmacology.

Recent filings

Filing Released Lang Actions
关于获批首家中药二级保护品种的公告
Regulatory Filings Classification · 82% confidence The document is a corporate announcement regarding the approval of a Traditional Chinese Medicine variety by the national regulatory authority. It does not contain financial statements, voting results, management changes, or share transactions. It is a general regulatory/compliance announcement, fitting the fallback category for miscellaneous filings that do not fit other specific categories.
2026-05-18 Chinese
关于2025年度股东会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is an announcement of the 2025 shareholders’ meeting resolutions with detailed vote counts on each proposal. It reports the formal voting results of an AGM rather than presenting a report, an attachment notice, or financial statements. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-18 Chinese
关于召开2026年第三次临时股东会通知的公告
Proxy Solicitation & Information Statement Classification · 83% confidence The document is a formal notice to shareholders about convening the 2026 third extraordinary general meeting, including meeting details, agenda items, registration procedures, voting methods, and a proxy authorization form (附件2). These are materials sent to shareholders to inform and solicit their votes, matching the definition of a Proxy Solicitation & Information Statement rather than an actual financial report or results announcement.
2026-05-12 Chinese
董事、高级管理人员薪酬管理制度（2026年5月）
Governance Information Classification · 82% confidence The document is titled “董事、高级管理人员薪酬管理制度” (Remuneration Management System for Directors and Senior Management) and lays out internal policies and procedures for setting, evaluating, and adjusting executive and director pay. It is not an announcement of a dividend or earnings, nor does it present actual financial results. Instead, it details corporate governance rules and systems related to remuneration. This aligns with the Governance Information category (CGR), which covers internal rules, board structures, and governance practices.
2026-05-12 Chinese
关于第六届董事会第二十六次会议决议的公告
Board/Management Information Classification · 85% confidence The document is an announcement of the sixth board of directors’ 26th meeting resolutions, detailing board meeting notice, attendance, and voting on items including amendments to director/executive compensation policies and the appointment of a board secretary. This is a corporate board/management information release regarding internal governance and senior management changes, fitting the “Board/Management Information” category.
2026-05-12 Chinese
关于向银行申请贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guizhou Bailing Pharmaceutical Group Co., Ltd. regarding the company's application for bank loans. It details the loan amounts, banks involved, loan terms, and the purpose of the loans. The document is a formal disclosure about financing activities, specifically about applying for new loans or renewing existing loans. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a report but an update on capital/financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short (1424 characters), and it is not merely announcing a report publication but providing substantive information about financing plans.
2026-01-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.